☆ 4.4 Article

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma

PANCREATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Identification and Validation of Potentially Clinically Relevant CpG Regions within the Class 2 Tumor Suppressor Gene SFRP1 in Pancreatic Cancer

Maximilian Hauschulz et al.

Summary: Pancreatic cancer is a highly lethal cancer with poor survival rates. In addition to surgery, chemotherapy is commonly used to prolong overall survival. However, the methylation of the SFRP1 gene in the promoter region may be associated with a poor response to gemcitabine treatment. This study aimed to identify key CpG sites in the SFRP1 gene promoter and evaluate their impact on overall survival.

CANCERS (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Oncology

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment

Asmaa Elrakaybi et al.

Summary: Epigenetic alterations play a significant role in the biology of PDAC, providing insights into its aggressive nature and offering new avenues for personalized therapies.

CANCERS (2022)

Add to Collection

Article Oncology

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma

Eramah Ermiah et al.

Summary: The present study investigated the associations of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels with clinicopathological variables and survival outcomes in Libyan patients with pancreatic ductal adenocarcinoma (PDAC). The results demonstrated that higher levels of CEA and CA19-9 were associated with more aggressive tumor characteristics, lower survival rates, and higher disease recurrence rates.

MOLECULAR AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy

Edgar Dahl et al.

Summary: A concept is presented for a new therapeutic approach that focuses on mimicking proteins encoded by tumor suppressor genes to restore the lost function in tumors. This approach may have a significant therapeutic effect on difficult-to-treat cancers.

CANCERS (2022)

Add to Collection

Article Oncology

Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

Benjamin Emil Stubbe et al.

Summary: Pancreatic adenocarcinoma (PDAC) is a disease with a poor prognosis, and there are currently no reliable blood-based biomarkers for predicting survival. This study examined the potential of phSFRP1 as an independent prognostic blood-based biomarker in PDAC patients, showing that patients with hypermethylation had poorer survival outcomes.

CANCERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma-An external validation study

Stine D. Henriksen et al.

Summary: The study validated a diagnostic prediction model based on hypermethylation of genes in PDAC patients' cfDNA, showing superior diagnostic value compared to CA 19-9 alone. Combining the diagnostic test with CA 19-9 could be a clinically useful biomarker for PDAC.

PANCREATOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Epigenetic Alterations in Pancreatic Cancer Metastasis

Sarah S. Wang et al.

Summary: Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDA), is a significant cause of cancer-related deaths in the United States. While genetic mutations driving PDA initiation and progression have been identified, the mechanisms underlying PDA metastasis remain elusive. It is suggested that epigenetic fluctuations may play a critical role in driving PDA metastasis.

BIOMOLECULES (2021)

Add to Collection

Article Oncology

The relation between inflammation-based parameters and survival in metastatic pancreatic cancer

Sema Turker et al.

Summary: This study evaluated the effect of tumor markers and inflammation parameters on survival in patients with metastatic pancreatic cancer. Age, CA19-9, and high NLR were identified as independent adverse prognostic factors for overall survival, while a chemotherapy regimen with specific drugs led to a significant increase in overall survival.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2021)

Add to Collection

Review Oncology

Epigenetics of SFRP1: The Dual Roles in Human Cancers

Rashidah Baharudin et al.

CANCERS (2020)

Add to Collection

Article Oncology

Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

Louise S. Rasmussen et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer

Sirin Cetin et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2020)

Add to Collection

Review Oncology

Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis

Francesco Natale et al.

CLINICAL EPIGENETICS (2019)

Add to Collection

Review Medicine, General & Internal

Application of Cell-free DNA Analysis to Cancer Treatment

Ryan B. Corcoran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer

Pedro L. S. Uson Junior et al.

JOURNAL OF GASTROINTESTINAL CANCER (2018)

Add to Collection

Article Oncology

Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors

Tatjana Maria Swerev et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma

Stine Dam Henriksen et al.

ONCOTARGET (2017)

Add to Collection

Article Cell Biology

Epigenetic Determinants of Cancer

Stephen B. Baylin et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)

Add to Collection

Article Oncology

Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma

Stine Dam Henriksen et al.

CLINICAL EPIGENETICS (2016)

Add to Collection

Article Oncology

Low SFRP1 Expression Correlates with Poor Prognosis and Promotes Cell Invasion by Activating the Wnt/β-Catenin Signaling Pathway in NPC

Xian-Yue Ren et al.

CANCER PREVENTION RESEARCH (2015)

Add to Collection

Article Oncology

Biomarker: Predictive or Prognostic?

Karla V. Ballman

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Mathematics, Interdisciplinary Applications

A competing risks approach to biologic interaction

Per Kragh Andersen et al.

LIFETIME DATA ANALYSIS (2015)

Add to Collection

Article Surgery

Prevalence of venous thromboembolism at diagnosis of upper gastrointestinal cancer

A. C. Larsen et al.

BRITISH JOURNAL OF SURGERY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling

Christof Bernemann et al.

MOLECULAR CANCER (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Secreted Frizzled Related Protein 1 Modulates Taxane Resistance of Human Lung Adenocarcinoma

Jin Ren et al.

MOLECULAR MEDICINE (2014)

Add to Collection

Article Oncology

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy

Todd M. Bauer et al.

CANCER (2013)

Add to Collection

Article Oncology

DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells

M. Zulfiquer Hossain et al.

ONCOTARGET (2013)

Add to Collection

Article Biochemistry & Molecular Biology

High recovery of cell-free methylated DNA based on a rapid bisulfite-treatment protocol

Inge Sokilde Pedersen et al.

BMC MOLECULAR BIOLOGY (2012)

Add to Collection

Article Oncology

Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers

Simon J. Cooper et al.

MOLECULAR CANCER THERAPEUTICS (2012)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy

Nazik Hammad et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Health Care Sciences & Services

Pseudo-observations in survival analysis

Per Kragh Andersen et al.

STATISTICAL METHODS IN MEDICAL RESEARCH (2010)

Add to Collection

Article Gastroenterology & Hepatology

Hypermethylation and aberrant expression of secreted fizzled-related protein genes in pancreatic cancer

Xian-Min Bu et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.